Mather Group LLC. raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,955 shares of the company’s stock after purchasing an additional 1,136 shares during the quarter. Mather Group LLC.’s holdings in Johnson & Johnson were worth $4,762,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Glassy Mountain Advisors Inc. bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $35,000. GW&K Investment Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $35,000. Dark Forest Capital Management LP boosted its stake in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after acquiring an additional 188 shares during the period. Retirement Financial Solutions LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $40,000. Finally, Ruedi Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $42,000. 67.94% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
JNJ has been the subject of several research analyst reports. Citigroup initiated coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price for the company. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Morgan Stanley lifted their price target on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. Atlantic Securities dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. Finally, Credit Suisse Group lifted their price target on Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $171.57.
Insider Transactions at Johnson & Johnson
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $164.23 on Friday. The stock has a market capitalization of $426.79 billion, a PE ratio of 34.36, a P/E/G ratio of 2.80 and a beta of 0.54. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The business has a fifty day moving average price of $160.73 and a two-hundred day moving average price of $163.98. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter in the previous year, the firm earned $2.67 EPS. Johnson & Johnson’s revenue was up 5.6% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were issued a dividend of $1.19 per share. The ex-dividend date was Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is 99.58%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 6/12 – 6/16
- Micron Building Goodwill In Asia, Near $2 Billion Investment
- Is Twilio On The Verge Of A Comeback?
- Broadcom: All-Time Highs But Still Good Value
- Leverage AI And Build A Fortress Portfolio With Adobe
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
